APA (7th ed.) Citation

Marlin, R., Jean-Laurent, M., Joachim, C., Vallard, A., Pennont, S., Suez-Panama, V., . . . Ebring, C. (2026). Feasibility of TP53 -Mutated ctDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS. Cancers, 18(7), 1102. https://doi.org/10.3390/cancers18071102

Chicago Style (17th ed.) Citation

Marlin, Regine, et al. "Feasibility of TP53 -Mutated CtDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS." Cancers 18, no. 7 (2026): 1102. https://doi.org/10.3390/cancers18071102.

MLA (9th ed.) Citation

Marlin, Regine, et al. "Feasibility of TP53 -Mutated CtDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS." Cancers, vol. 18, no. 7, 2026, p. 1102, https://doi.org/10.3390/cancers18071102.